Related Experiment Video
Updated: Sep 19, 2025
Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
Published on: February 8, 2017
Nanoparticle-driven drug delivery system for cardiovascular treatment
Raj Patel1, Dhruvi Patel2, Unnati Dani3
1Banas Medical College and Research Institute, Palanpur, Gujarat, India.
Insights
Cardiovascular disease (CVD) nanomedicine utilizes nanoparticles for targeted drug delivery, offering a safe and efficient treatment approach. This review highlights metal, lipid, and polymer nanoparticles for conditions like hypertension and myocardial infarction.
Area of Science:
- Cardiology
- Nanomedicine
- Biomedical Engineering
Background:
- Cardiovascular disease (CVD) is a leading global health concern, affecting millions and causing significant mortality.
- Current treatments face challenges, necessitating innovative therapeutic strategies.
- Nanomaterials offer unique properties for advanced medical applications.
Purpose of the Study:
- To review the clinical opportunities and therapeutic potential of nanomedicine in treating cardiovascular diseases.
- To focus on nanoparticle-based drug delivery systems for cardiac conditions.
Main Methods:
- Review of recent advances in nanoparticle-based therapeutics for CVD.
- Concentration on metal, lipid, and polymer nanoparticles for drug delivery.
- Emphasis on targeted delivery to cardiac tissues.
Main Results:
- Nanoparticles demonstrate increased target specificity and sensitivity for cardiac tissues.
- Heart-targeted nanocarriers show promise for treating hypertension, atherosclerosis, and myocardial infarction.
- Nanomedicine offers a safe and efficient drug delivery method for CVD.
Conclusions:
- Nanoparticle-based therapeutics represent a significant advancement in cardiovascular nanomedicine.
- Drug delivery via nanoparticles holds substantial therapeutic potential for clinical applications in CVD.
- Emerging nanomedicine approaches are crucial for addressing the challenges in CVD treatment.
Abstract:
Cardiovascular disease (CVD) is the world's major concern affecting the heart, blood arteries, and the blood that flows through and between them, making it a significant obstacle to contemporary healthcare practices. Approximately one in three individuals has a CVD, and many of them have several, overlapping diseases that might eventually result in catastrophic events such as a heart attack or stroke. The previous century opened the door for progress of life-saving drugs and treatment modalities. Recent developments in nanomaterials provide novel approaches for the treatment of CVD. Due to their unique properties, which include increased target specificity, sensitivity, and both active and passive targeting of cardiac tissues, the use of nanoparticles as carriers has received a lot of attention in the field of cardiology. Drug delivery using heart-targeted nanocarriers is a safe, efficient method of treating heart-related conditions such as hypertension, atherosclerosis, and myocardial infarction. Here, we highlight significant clinical opportunities in the quickly emerging field of CVD nanomedicine. This review concentrates on the use of nanoparticle-based therapeutics in CVD and provides a key take away regarding the use of metal, lipid, and polymer-based nanoparticle in CVD treatment. In this review, we emphasize recent advances in the use of nanomedicine to treat CVD and the therapeutic potential of drug delivery via nanoparticles in clinical prospects.
